AF Association Symposia 1 - AF detection in different contexts- how do we get it right for the local population
	Arrhythmia Alliance and Venice Arrhythmias Joint Session
	Idiopathic Ventricular Fibrillation
	AF Association Symposia 3 - Correct - Drugs vs Ablation session

AF Association Symposia 1 - AF detection in different contexts- how do we get it right for the local population -

	Chair: Prof Ben Freedman, Prof Jeroen Hendriks		Sydney, AU, Maastricht, NL; Adelaide, AU
	What works for whom in AF screening- a realist review	Dr Coral Hanson	Edinburgh, UK
	AF screening in indigenous populations	Mr Suud Nahdi	Sydney, AU
	Rural screening for AF	Dr Jessica Orchard	Sydney, AU
	Pharmacy based AF screening
	AF Detection in Vaccine Clinics	Dr Nithya Nanda, Mrs Trudie Lobban	Slough, UK, Winchester, UK
	Discussion

Arrhythmia Alliance and Venice Arrhythmias Joint Session -

	Chair: Prof Carlos Morillo		Calgary, CA
	Lifestyle and risk factors modification: implementation and results	Dr Antonio Rossillo	Vicenza, IT
	Rhythm vs. rate control: is it time to change strategy?	Dr Sakis Themistoclakis	Venice-Mestre, IT
	New technologies for AF ablation: impact on clinical outcomes	Dr Andrea Natale	Austin, US
	Cardiac neuro ablation/modulation of AF: where are we and where are we going?	Prof Tolga Aksu	Istanbul, TR
	LAA closure: first choice or last chance? (pro)	Dr Luigi Di Biase	New York, US
	LAA closure: first choice or last chance? (con)	Prof Tim Betts	Oxford, UK

Idiopathic Ventricular Fibrillation -

	Chair: Prof Bernard Belhassen, Prof Pier Lambiase		Tel-Aviv, IL, London, UK
	How common is idiopathic VF?	Prof Giulio Conte	Lugano, CH
	How to diagnose idiopathic VF	Prof Andrew Krahn	Columbia, US
	Genetic Testing in idiopathic VF	Dr Greg Mellor	Cambridge, UK
	Short-coupled VF idiopathic ventricular fibrillation: Diagnosis and management	Prof Bernard Belhassen	Tel-Aviv, IL

AF Association Symposia 3 - Correct - Drugs vs Ablation session -

	Chair: Prof Dhiraj Gupta, Prof Sanjiv Narayan		Liverpool, UK, Palo Alto, US
	Do the outcomes of early rhythm control with catheter ablation extend to patients with persistent AF too?	Prof Dhiraj Gupta	Liverpool, UK
	The impact of anti-arrhythmic drugs on Atrial fibrillation burden	Prof Paulus Kirchhof	Hamburg, DE
	The role of omega-3 fatty acids in atrial fibrillation management	Dr Christine Albert	Los Angeles, US
	Machine Learning to Guide Ablation and Drug Therapy for Atrial Fibrillation	Prof Sanjiv Narayan	Palo Alto, US
	What does Surgical Therapy for Atrial Fibrillation add to Catheter Ablation?	Dr David DeLurgio	Atlanta, US
	Future Trials to Advance Ablation Therapy for Atrial Fibrillation